A randomized trial of a 6-week course of celecoxib on proteinuria in diabetic kidney disease.

A randomized trial of a 6-week course of celecoxib on proteinuria in diabetic kidney disease. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

A randomized trial of a 6-week course of celecoxib on proteinuria in diabetic kidney disease. Abstract Text:

Marvin Sinsakul,Mohammed Sika,Roger Rodby,John Middleton,Yu Shyr,Heidi Chen,Ernest Han,Ruediger Lehrich,Stephen Clyne,Gerald Schulman,Raymond Harris,Julia Lewis,Marvin Sinsakul,Mohammed Sika,Roger Rodby,John Middleton,Yu Shyr,Heidi Chen,Ernest Han,Ruediger Lehrich,Stephen Clyne,Gerald Schulman,Raymond Harris,Julia Lewis,

BACKGROUND: Preclinical data suggest that cyclooxygenase 2 inhibitors decrease proteinuria and preserve glomerular structure in animal models of diabetic nephropathy. The objective of this study is to compare the efficacy and safety of celecoxib with placebo for decreasing proteinuria in patients with diabetic nephropathy. STUDY DESIGN: Placebo-controlled double-blinded crossover design. SETTING & PARTICIPANTS: 24 patients with type 1 or 2 diabetes mellitus, proteinuria with protein of 500 mg/d or greater, and serum creatinine level of 3.0 mg/dL or less. INTERVENTION: Patients were randomly assigned to: (1) 6 weeks of celecoxib followed by a 3-week washout period, followed by 6 weeks of placebo followed by another 3-week washout; or (2) 6 weeks of placebo followed by a 3-week washout, followed by 6 weeks of celecoxib followed by another 3-week washout period. All patients were administered quinapril, 20 to 40 mg/d, or irbesartan, 150 to 300 mg/d. All patients were administered aspirin, 81 mg/d. OUTCOMES & MEASUREMENTS: Proteinuria was assessed by means of protein-creatinine ratio. Data were analyzed using the mixed-effect statistical model. RESULTS: There was no significant difference in urinary proteinuria after 6 weeks of treatment with placebo or celecoxib (proteinuria ratio, celecoxib versus placebo, 1.041; 95% confidence interval, 0.846 to 1.282). Celecoxib had no significant effect on potassium or estimated glomerular filtration rate. Frequencies of adverse events were similar between the placebo and celecoxib treatments. LIMITATIONS: This pilot study was not designed to evaluate the safety or long-term clinical effects of celecoxib. CONCLUSIONS: Celecoxib, 200 mg/d, for 6 weeks did not alter proteinuria. Few adverse events were noted in this high-risk population.

A randomized trial of a 6-week course of celecoxib on proteinuria in diabetic kidney disease. Publishing Authors By Initials

M Sinsakul,M Sika,R Rodby,J Middleton,Y Shyr,H Chen,E Han,R Lehrich,S Clyne,G Schulman,R Harris,J Lewis,M Sinsakul,M Sika,R Rodby,J Middleton,Y Shyr,H Chen,E Han,R Lehrich,S Clyne,G Schulman,R Harris,J Lewis,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

A randomized trial of a 6-week course of celecoxib on proteinuria in diabetic kidney disease. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: American journal of kidney diseases : the official

VOLUME: 50

Page Numbers: 946-51

Journal Abbreviation: Am. J. Kidney Dis.

ISSN: 1523-6838

DAY: 26

MONTH: Dec

YEAR: 2007

A randomized trial of a 6-week course of celecoxib on proteinuria in diabetic kidney disease. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8110075

A randomized trial of a 6-week course of celecoxib on proteinuria in diabetic kidney disease. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: A randomized trial of a 6-week course of celecoxib on proteinuria in diabetic kidney disease. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for A randomized trial of a 6-week course of celecoxib on proteinuria in diabetic kidney disease.

AFFILIATION: Rush University Medical Center, Chicago, IL 60607, USA. marvin_v_sinsakul@rush.edu

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Am J Kidney Dis

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

A randomized trial of a 6-week course of celecoxib on proteinuria in diabetic kidney disease Related Publications

• 64Cu-azabicyclo[3.2.2]nonane thiosemicarbazone complexes: radiopharmaceuticals for PET of topoisomerase II expression in tumors.
• A state space analysis of emotion and flexibility in parent-child interactions.
• Analysis of the volatile components of cheddar cheese by direct thermal desorption-GC x GC-TOF/MS.
• Brain activation when hearing one's own and others' names.
• Candida albicans biofilms produce antifungal-tolerant persister cells.
• Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial.
• Conjugating berberine to a multidrug efflux pump inhibitor creates an effective antimicrobial.
• Contemporary developments in thin-layer chromatography.
• Determinants of plasma HDL concentrations and reverse cholesterol transport.
• Dopamine innervation of the monkey mediodorsal thalamus: Location of projection neurons and ultrastructural characteristics of axon terminals.
• Environmental impacts of dredging on seagrasses: a review.
• Hip Abductor and Knee Extensor Muscle Strength of Children with and without Down Syndrome.
• Hospital disaster preparedness in Los Angeles County.
• Identification and characterization of a cell surface protein of Prevotella intermedia 17 with broad-spectrum binding activity for extracellular matrix proteins.
• Intracellular cGMP may promote Ca2+-dependent and Ca2+-independent release of catecholamines from sympathetic nerve terminals.
• L-beta,beta-dimethylcysteine attenuates the haemodynamic responses elicited by systemic injections of peroxynitrite in anaesthetized rats.
• Metal-organic complexation in the marine environment.
• Multiwire Gas Proportional Counters: Decrepit Antiques or ClassicPerformers?
• Open the door whenever opportunity knocks.
• Production of non-standard PET radionuclides and the application of radiopharmaceuticals labeled with these nuclides.
• Quality of manufacturer provided information on safety and efficacy claims for dietary supplements for colonic health.
• Recent advances in health professional training on substance abuse disorders.
• Regulation of CRAC channel activity by recruitment of silent channels to a high open-probability gating mode.
• Sex-linked congenital deafness.
• Spontaneous uterine infections are associated with elevated prostaglandin F(2)alpha metabolite concentrations in postpartum dairy cows.
• The early alcoholism treatment movement in Australia, 1859-1939.
• The relationship between plasma homocysteine, red cell folate and plasma vitamin B12 in a sample of the New South Wales Central Coast population.
• Transcranial magnetic stimulation: a possible treatment for TBI.
• Two novel human serine/threonine kinases with homologies to the cell cycle regulating Xenopus MO15, and NIMA kinases: cloning and characterization of their expression pattern.
• Uterine involution and postpartum ovarian activity in Nili-Ravi buffaloes.